AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 101 min read$PRCT

Nouri Alaleh sold $8K of PRCT

Nouri Alaleh (EVP, CLO, CORP. SEC.) sold 285 shares of PROCEPT BioRobotics Corp (PRCT) at $28.48 on 2026-06-08.

Original reporting
SEC EDGAR · Nouri Alaleh
Published Jun 10, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PRCT
Neutral
medium confidence
Mentioned
$PRCT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRCTNeutralLow
01

Why it matters

This provides incremental ownership/behavior information for an executive but does not introduce new company fundamentals or corporate actions.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the disclosed value is small and unlikely to drive repricing by itself.

03

What to watch

Insider sales often reflect diversification, tax planning, or pre-scheduled personal liquidity needs; without additional context, directional inference is weak.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10; transaction dated 2026-06-08.

Background

The article is a SEC Form 4 insider transaction disclosure (open-market sale) for Procept BioRobotics.

Company-level read

Ticker impact

$PRCTNeutralMedium confidence
Context

Procept BioRobotics disclosed an insider open-market sale by EVP/CLO/CORP officer Nouri Alaleh: 285 shares sold at $28.4790 on 2026-06-08.

Expected impact

Low likelihood of a sustained price move; any near-term reaction would be sentiment-driven and likely fade.

Evidence & confidence

The filing is primary-source (Form 4) but the transaction size (~$8.1k) is modest and does not indicate a corporate event (no guidance, deal, or enforcement action).

Market effects

Sector

No clear sector read-through from a single small insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, but the dollar amount is too small to be a strong signal.

Key entities

  • issuer
    PROCEPT BioRobotics Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Nouri Alaleh

    EVP, CLO, CORP officer who sold 285 shares.

Read at source← All news

Related articles

AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min